Skip to content

Search the library by company, product or topic.

↵open↑↓navigateescclose

Holmusk

Health data science company whose NeuroBlu platform provides de-identified longitudinal behavioural-health and neurology records, with an analytics workspace, to life-sciences and research users.

holmusk.com

At a glance

Business model
B2B
Products profiled
1
Operating markets
4 markets
Sources cited
3
In the library since
24 September 2026

What it does

Holmusk's NeuroBlu platform provides research-grade real-world data, de-identified patient records in behavioural health and neurology, with a web application and an analytics workspace in R, Python or SQL, for drug discovery, medical affairs, research and payers.

What the company says

The company’s own statements, attributed to it and not presented as established fact.

The company says it is building the largest real-world evidence platform, starting with behavioural health; in May 2026 it said NeuroBlu covered over 46 million de-identified patient lives after adding two neurological health systems, Alzheimer's disease biomarker data, claims linkage and neuroimaging encounter data.

The company's site lists Singapore, New York, London and Basel without naming a headquarters, so the headquarters is not recorded and the four are recorded as operating markets. The registered name, founding year and funding stage are not recorded.

Products

More of Recent HealthTech